German firm Evotec, which acquired biotech company Renovis for about $152 million in a stock agreement last year, announced it will shut down the unit as it reorganizes its drug discovery and development functions to save costs and enhance efficiency. A spokeswoman for Evotec said the move will lead to about 45 job cuts and the transfer of Renovis' drug programs to Evotec's operations in Europe.

Related Summaries